Ligand id: 1915

Name: PGI2

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pgi2

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 86.99
Molecular weight 352.22
XLogP 2.98
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the long term treatment of primary pulmonary hypertension.
Mechanism Of Action and Pharmacodynamic Effects
Activates the prostacylin receptor which causes the production of cAMP via adenylyl cyclase siganalling. cAMP then inhibits platelet activation. Binding of epoprostenol to prostacyclin receptors raises cAMP levels in the cytosol, which in turn activates protein kinase A. Protein kinase A phosphorylates and inhibits myosin light-chain kinase which leads to smooth muscle relaxation and vasodilation.